Second Sight holds a
performance score of 12 on a scale of zero to a hundred. The entity has a beta of 12.6034, which indicates a somewhat significant risk relative to the market. Let's try to break down what Second's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Second Sight will likely underperform. Although it is essential to pay attention to
Second Sight current price movements, it is also good to be reasonable about what you can do with equity historical returns. Our philosophy towards measuring future potential of any stock is to look not only at its past charts but also at the business as a whole, including all
available fundamental and
technical indicators. To evaluate if Second Sight expected return of 7.69 will be sustainable into the future, we have found twenty-seven different
technical indicators, which can help you to check if the expected returns are sustainable. Use Second Sight
maximum drawdown, and the
relationship between the
information ratio and
expected short fall to analyze future returns on Second Sight.
The successful prediction of Second Sight
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Second Sight Medical, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Second Sight based on Second Sight hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Second Sight's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Second Sight's related companies.
Use Technical Analysis to project Second expected Price
Second Sight technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
A focus of Second Sight technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Second Sight trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...What is driving Second Sight Investor Appetite?
This firm reported the previous year's revenue of 497
K. Net Loss for the year was (21.46
M) with profit before overhead, payroll, taxes, and interest of 1.23
M.
| 2018 | 2019 | 2020 | 2021 (projected) |
Receivables Turnover | 5.91 | 7.05 | 6.34 | 5.9 | PPandE Turnover | 5.93 | 3.15 | 2.83 | 3.35 |
Deferred Revenue Breakdown
Second Sight Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Deferred Revenue is likely to grow to about 309.4
K this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Second Sight Deferred Revenue is relatively stable at the moment as compared to the past year. Second Sight reported last year Deferred Revenue of 301,500
| 2014 | 4.67 Million |
| 2015 | 2.52 Million |
| 2016 | 189,000 |
| 2017 | 48,000 |
| 2018 | 167,000 |
| 2019 | 335,000 |
| 2020 | 301,500 |
| 2021 | 309,434 |
Our perspective of the latest Second Sight spike
Latest mean deviation is at 16.17. Second Sight is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Second Sight implied risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Second Sight's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Second Sight's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Takeaway on Second Sight Investment
While many other companies under the medical devices industry are still a bit expensive, Second Sight may offer a potential longer-term growth to retail investors. While some retail investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Second Sight.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Second Sight Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com